ECSP23004827A - Proteínas actrii para el tratamiento de la hipertensión pulmonar - Google Patents

Proteínas actrii para el tratamiento de la hipertensión pulmonar

Info

Publication number
ECSP23004827A
ECSP23004827A ECSENADI20234827A ECDI202304827A ECSP23004827A EC SP23004827 A ECSP23004827 A EC SP23004827A EC SENADI20234827 A ECSENADI20234827 A EC SENADI20234827A EC DI202304827 A ECDI202304827 A EC DI202304827A EC SP23004827 A ECSP23004827 A EC SP23004827A
Authority
EC
Ecuador
Prior art keywords
treatment
pulmonary hypertension
actrii proteins
actrii
proteins
Prior art date
Application number
ECSENADI20234827A
Other languages
English (en)
Inventor
Gang Li
Patrick Andre
Sachindra Joshi
Ravindra Kumar
Peter Linde
Oliveira Pena Janethe De
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of ECSP23004827A publication Critical patent/ECSP23004827A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

En algunos aspectos, la divulgación se refiere a composiciones y métodos que comprenden polipéptidos ActRII para tratar, prevenir o reducir la tasa de progresión y/o la gravedad de la hipertensión arterial pulmonar, particularmente el tratamiento, prevención o reducción de la tasa de progresión y/o la gravedad de una o más complicaciones asociadas a la hipertensión arterial pulmonar.
ECSENADI20234827A 2020-06-23 2023-01-20 Proteínas actrii para el tratamiento de la hipertensión pulmonar ECSP23004827A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063042722P 2020-06-23 2020-06-23
US202063084409P 2020-09-28 2020-09-28
US202063112513P 2020-11-11 2020-11-11
US202163188141P 2021-05-13 2021-05-13

Publications (1)

Publication Number Publication Date
ECSP23004827A true ECSP23004827A (es) 2023-03-31

Family

ID=79281768

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20234827A ECSP23004827A (es) 2020-06-23 2023-01-20 Proteínas actrii para el tratamiento de la hipertensión pulmonar

Country Status (15)

Country Link
US (3) US20230226146A1 (es)
EP (1) EP4168037A4 (es)
JP (1) JP7854402B2 (es)
KR (1) KR20230026435A (es)
CN (1) CN115989035A (es)
AU (1) AU2021296421A1 (es)
BR (1) BR112022025644A2 (es)
CA (1) CA3182838A1 (es)
CL (1) CL2022003686A1 (es)
CO (1) CO2022018719A2 (es)
EC (1) ECSP23004827A (es)
IL (1) IL299189A (es)
MX (1) MX2022016237A (es)
PE (1) PE20230783A1 (es)
WO (1) WO2021262718A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
CA3176735A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION
PE20230783A1 (es) * 2020-06-23 2023-05-11 Acceleron Pharma Inc Proteinas actrii para el tratamiento de la hipertension pulmonar
CA3260897A1 (en) * 2022-08-10 2024-02-15 Gb002, Inc. Polytherapy based on a tyrosine kinase inhibitor and a type 2 activin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH)
WO2024054985A2 (en) * 2022-09-09 2024-03-14 Keros Therapeutics, Inc. Methods of administering an activin type iib variant
WO2024238263A1 (en) * 2023-05-12 2024-11-21 Merck Sharp & Dohme Llc Methods of improving lung diffusion capacity in a patient with pulmonary arterial hypertension
CN121127502A (zh) * 2023-05-15 2025-12-12 宜明凯尔生物医药技术(上海)有限公司 用于治疗肺高压的重组融合蛋白
WO2025122752A1 (en) * 2023-12-07 2025-06-12 Merck Sharp & Dohme Llc Methods for treating pulmonary arterial hypertension with activin receptor type iia (actriia) proteins and/or variants thereof
WO2025237307A1 (zh) * 2024-05-14 2025-11-20 苏州康宁杰瑞生物科技有限公司 凝血因子FXI/FXIa抑制剂用于治疗肺动脉高压和/或高血压
CN120888004B (zh) * 2025-09-30 2026-04-03 齐鲁制药有限公司 包含索特西普和其变体的组合物以及相关方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41052A (fr) * 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3298034A4 (en) * 2015-05-20 2019-02-13 Celgene Corporation IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
CN116531490A (zh) * 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
KR20200109330A (ko) * 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
WO2019217715A1 (en) * 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
PE20230783A1 (es) * 2020-06-23 2023-05-11 Acceleron Pharma Inc Proteinas actrii para el tratamiento de la hipertension pulmonar

Also Published As

Publication number Publication date
MX2022016237A (es) 2023-03-08
WO2021262718A1 (en) 2021-12-30
EP4168037A1 (en) 2023-04-26
US20250082722A1 (en) 2025-03-13
KR20230026435A (ko) 2023-02-24
EP4168037A4 (en) 2024-07-17
US20230226146A1 (en) 2023-07-20
BR112022025644A2 (pt) 2023-03-07
AU2021296421A1 (en) 2023-01-19
CA3182838A1 (en) 2021-12-30
CO2022018719A2 (es) 2023-03-07
CN115989035A (zh) 2023-04-18
IL299189A (en) 2023-02-01
JP2023534143A (ja) 2023-08-08
US20250249070A1 (en) 2025-08-07
JP7854402B2 (ja) 2026-05-01
PE20230783A1 (es) 2023-05-11
CL2022003686A1 (es) 2023-05-26

Similar Documents

Publication Publication Date Title
CL2022003686A1 (es) Proteínas actrii para el tratamiento de la hipertensión arterial pulmonar (hap).
CO2022016210A2 (es) Proteínas actrii y su uso en el tratamiento de la hipertensión pulmonar postcapilar
CY1124277T1 (el) Συνθεσεις που περιλαμβανουν πολυπεπτιδα actriia για χρηση στη θεραπεια πνευμονικης υπερτασης
BR112022022401A2 (pt) Terapia de combinação tripla para aumentar o extermínio de células cancerígenas em cânceres com baixa imunogenicidade
PH12022550438A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MX2022002489A (es) Composiciones de neurotoxinas para usarse en el tratamiento contra cefalea.
CO6300826A2 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf
AR059066A1 (es) Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
MX2020002194A (es) Uso de oxido nitrico inhalado para el tratamiento de la hipertension pulmonar asociada con enfermedades pulmonares.
CL2022002540A1 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina
ES2571956T3 (es) Uso médico de la alfa 1-microglobulina antioxidante y eliminadora de radicales
MX2009005066A (es) Composiciones para mejorar la condicion y apariencia de la piel y metodos para su uso.
MX2018005322A (es) Composicion dermocosmetica, proceso de produccion de la composicion topica, metodo para fortalecer la fragilidad de las uñas y uso de la composicion.
BR112017014914A2 (pt) terapia combinada para hipertensão pulmonar
ES2421407T3 (es) Agente y composición para la curación de heridas
WO2022192420A3 (en) Actrii proteins and uses thereof
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
ECSP24002381A (es) Proteínas actrii y usos de las mismas
UY39504A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
MX2024014771A (es) Terapia combinada
MX2022004422A (es) Metodo para el tratamiento del cabello.
MX2024006091A (es) Metodo para el tratamiento de una enfermedad de esclerodermia.
MX2022010216A (es) Usos y composiciones a base de polifenoles para mejorar la biodisponibilidad oral del hidroxitirol.
BR112022011207A2 (pt) Composições para cuidados pessoais e métodos para estas
AR037968A1 (es) Extracto acuoso de salvado de arroz y uso del mismo como aditivo en pastas de pescado